Prashant Kapoor, MD

Mayo Clinic
Rochester, Minnesota

Prashant Kapoor, MD, FACP, is a Consultant and an Associate Professor of Medicine at Mayo Clinic, Rochester, Minnesota. He was awarded the Kurtz Myeloma Research Fellowship at Mayo Clinic in 2008 following which he commenced his clinical fellowship training in Hematology and Oncology at Mayo Clinic. Upon completion of his training in 2012, he was invited to serve as faculty in the Division of Hematology, Mayo Clinic.

He is a recipient of several awards, including the American Society of Clinical Oncology (ASCO) Merit Award, Department of Medicine (DOM) Career Development Award, Research Innovation Award, Transplant Center Scholar Award and the Department of Medicine Faculty Scholar Award.

His research is focused in evaluating novel agents in plasma cell disorders. He is a PI of several investigator-initiated and industry-sponsored clinical trials. He has served on the Mayo Clinic Institutional Review Board, and is currently a member of the Mayo Cancer Center Data Safety Monitoring Committee.

He is a passionate educator and has presented his work at national and international forums. He has served on the Editorial Board of the American Society of Hematology (ASH) Daily News and is the Myeloma Section Editor of Current Hematologic Malignancy Reports and Co-Site Editor for Myeloma Section of JNCCN 360. He has over 250 publications in prestigious journals, including The Lancet, JAMA Oncology, Journal of Clinical Oncology, The Lancet Oncology, Blood, The Lancet Haematology, and Leukemia.

He is a fellow at the American College of Physicians, and an active member of the International Myeloma Working Group, ASH, ASCO and the International Myeloma Society.

Disclosure information not submitted.

Presentation(s):

• Session I: WM I

  Friday, June 17, 2022
  1:00 PM – 2:35 PM

• The Genomics of Waldenström Macroglobulinemia

  Friday, June 17, 2022
  1:05 PM – 1:25 PM

• Debate: BTK Inhibitors vs Bendamustine-Rituximab (BR) as Primary Therapy - BR

  Friday, June 17, 2022
  1:45 PM – 1:52 PM

• Debate: BTK Inhibitors vs Bendamustine-Rituximab (BR) as Primary Therapy - DISCUSSION

  Friday, June 17, 2022
  1:59 PM – 2:05 PM

• Q&A and Polling

  Friday, June 17, 2022
  2:05 PM – 2:35 PM

• Session II: WM II

  Friday, June 17, 2022
  2:55 PM – 4:30 PM

• Case Discussion: When to Wait and When to Treat

  Friday, June 17, 2022
  3:40 PM – 4:00 PM

• Q&A and Polling

  Friday, June 17, 2022
  4:00 PM – 4:30 PM